July 31, 2017 / 2:35 AM / 2 years ago

BRIEF-Otsuka Holdings unit says ABILIFY MAINTENA® for extended-release injectable suspension approved by U.S. FDA

July 31 (Reuters) - Otsuka Holdings Co Ltd

* Says unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced ABILIFY MAINTENA®(aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and drug administration for the maintenance monotherapy treatment of bipolar I disorder (BP-I) in adults

Source text in Japanese:goo.gl/faYVAm

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below